• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

The Top 5 Biosimilars Articles for the Week of August 13

Article

The Center for Biosimilars® recaps the top news for the week of August 13, 2018.

Transcript:

Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of August 13.

Number 5: AbbVie has filed suit against biosimilar developer Sandoz over its proposed Humira biosimilar.

Number 4: Fifty-two-week results of a phase 3 study, which included a switch from Humira to SB5, show that switching led to no change in treatment-emergent adverse events.

Number 3: The clinical director of Ireland’s health technology assessment body has called for all new patients to start treatment with biosimilars rather than with reference products.

Number 2: The Federal Trade Commission has called on the FDA to use its authority to foster biosimilar competition.

Number 1: CVS Caremark says that it will use data from the Institute for Clinical and Economic Review in making coverage decisions.

Finally, last week, our e-newsletter asked whether you think that the United States should follow Australia’s lead in using “uptake drivers” for biosimilars.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit centerforbiosimilars.com.

Recent Videos
Sophia Humphreys, PharmD
Ha Kung Wong, JD.
Prerakkumar Parikh, PharmD
Cencora's Corey Ford
Brian Biehn
GBW 2023 webinar
Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University,
Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University,
Fran Gregory, PharmD, MBA
Julie Reed, MS
Related Content
© 2024 MJH Life Sciences

All rights reserved.